Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) - Equities research analysts at Leerink Partnrs lifted their Q3 2024 earnings per share estimates for shares of Sage Therapeutics in a report issued on Tuesday, October 15th. Leerink Partnrs analyst M. Goodman now forecasts that the biopharmaceutical company will post earnings of ($1.39) per share for the quarter, up from their previous estimate of ($1.51). The consensus estimate for Sage Therapeutics' current full-year earnings is ($6.46) per share. Leerink Partnrs also issued estimates for Sage Therapeutics' Q4 2024 earnings at ($1.36) EPS, FY2024 earnings at ($6.25) EPS, FY2025 earnings at ($2.75) EPS, FY2026 earnings at ($2.65) EPS, FY2027 earnings at ($2.95) EPS and FY2028 earnings at ($3.00) EPS.
Several other research analysts have also recently weighed in on the company. Needham & Company LLC reaffirmed a "hold" rating on shares of Sage Therapeutics in a research report on Thursday. The Goldman Sachs Group reduced their price target on Sage Therapeutics from $19.00 to $11.00 and set a "neutral" rating for the company in a research report on Friday, July 26th. HC Wainwright reiterated a "neutral" rating and issued a $25.00 price objective on shares of Sage Therapeutics in a report on Wednesday, October 9th. Bank of America reduced their target price on shares of Sage Therapeutics from $11.00 to $6.00 and set an "underperform" rating for the company in a report on Wednesday, October 9th. Finally, TD Cowen lowered shares of Sage Therapeutics from a "buy" rating to a "hold" rating and lowered their price target for the company from $16.00 to $10.00 in a research note on Tuesday, July 30th. Two investment analysts have rated the stock with a sell rating, eighteen have given a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $13.76.
View Our Latest Analysis on Sage Therapeutics
Sage Therapeutics Stock Performance
NASDAQ SAGE traded up $0.36 on Friday, reaching $7.57. The company had a trading volume of 441,412 shares, compared to its average volume of 980,930. The company's fifty day moving average is $7.56 and its 200-day moving average is $10.58. Sage Therapeutics has a 1-year low of $5.84 and a 1-year high of $28.26. The firm has a market capitalization of $462.15 million, a price-to-earnings ratio of -0.98 and a beta of 0.91.
Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last released its quarterly earnings results on Wednesday, July 31st. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, missing the consensus estimate of ($1.68) by ($0.02). Sage Therapeutics had a negative net margin of 458.30% and a negative return on equity of 55.87%. The company had revenue of $8.65 million during the quarter, compared to analyst estimates of $8.85 million. During the same quarter last year, the company earned ($2.68) EPS. The firm's quarterly revenue was up 249.8% compared to the same quarter last year.
Institutional Trading of Sage Therapeutics
A number of hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. grew its stake in Sage Therapeutics by 8.1% in the 1st quarter. Vanguard Group Inc. now owns 5,751,373 shares of the biopharmaceutical company's stock valued at $107,781,000 after buying an additional 432,013 shares during the last quarter. Bellevue Group AG increased its stake in shares of Sage Therapeutics by 27.1% during the first quarter. Bellevue Group AG now owns 4,465,544 shares of the biopharmaceutical company's stock worth $83,684,000 after purchasing an additional 952,193 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in Sage Therapeutics by 69.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 811,934 shares of the biopharmaceutical company's stock worth $15,217,000 after purchasing an additional 333,805 shares during the last quarter. Federated Hermes Inc. bought a new stake in Sage Therapeutics in the 2nd quarter valued at $7,281,000. Finally, Renaissance Technologies LLC grew its holdings in Sage Therapeutics by 1,476.6% in the 2nd quarter. Renaissance Technologies LLC now owns 553,396 shares of the biopharmaceutical company's stock valued at $6,010,000 after buying an additional 518,296 shares in the last quarter. Institutional investors and hedge funds own 99.22% of the company's stock.
Sage Therapeutics Company Profile
(
Get Free Report)
Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.
Recommended Stories
Before you consider Sage Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sage Therapeutics wasn't on the list.
While Sage Therapeutics currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.